Severe Ocrelizumab-Induced Enterocolitis Treated Successfully With Ustekinumab

As biologics have become the mainstay of treatment for many autoimmune diseases, their adverse effects are also being identified and described increasingly in the literature. Colitis associated with biologics is a previously described phenomenon in the literature with anti-CD20 (rituximab). The mechanism was thought to be related to B-lymphocyte depletion. We present a case of severe enterocolitis induced by another anti-CD20 monoclonal antibody (ocrelizumab), highlighting a potentially promising therapeutic approach. We performed an extensive literature review and found 4 similar cases. Our case is the first to be salvaged successfully with ustekinumab.